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Methodology
The Extrapolation Performance of Survival Models for Data With a Cure
Fraction: A Simulation Study
Benjamin Kearns, MSc, PhD, Matt D. Stevenson, BSc, PhD, Kostas Triantafyllopoulos, MSc, PhD, Andrea Manca, MSc, PhD
A B S T R A C T
Objectives: Curative treatments can result in complex hazard functions. The use of standard survival models may result in
poor extrapolations. Several models for data which may have a cure fraction are available, but comparisons of their
extrapolation performance are lacking. A simulation study was performed to assess the performance of models with and
without a cure fraction when fit to data with a cure fraction.
Methods: Data were simulated from a Weibull cure model, with 9 scenarios corresponding to different lengths of follow-up
and sample sizes. Cure and noncure versions of standard parametric, Royston-Parmar, and dynamic survival models were
considered along with noncure fractional polynomial and generalized additive models. The mean-squared error and bias
in estimates of the hazard function were estimated.
Results: With the shortest follow-up, none of the cure models provided good extrapolations. Performance improved with
increasing follow-up, except for the misspecified standard parametric cure model (lognormal). The performance of the
flexible cure models was similar to that of the correctly specified cure model. Accurate estimates of the cured fraction
were not necessary for accurate hazard estimates. Models without a cure fraction provided markedly worse extrapolations.
Conclusions: For curative treatments, failure to model the cured fraction can lead to very poor extrapolations. Cure models
provide improved extrapolations, but with immature data there may be insufficient evidence to choose between cure and
noncure models, emphasizing the importance of clinical knowledge for model choice. Dynamic cure fraction models were
robust to model misspecification, but standard parametric cure models were not.
Keywords: cure models, flexible survival models, forecasting, survival extrapolation.
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Introduction
Estimates of future survival are frequently a key component of
technology appraisals (TAs). Decisions about whether a technol-
ogy should be funded are often sensitive to the extrapolation
approach used.1 Hence, it is important that appropriate methods
are used when generating extrapolations. In the last few years,
there has been a growing interest in generating extrapolations for
curative treatments, such as immuno-oncology drugs.2-5 These
present unique challenges, because the presence of a cured frac-
tion creates heterogeneity in the survivor (and hazard) functions,
resulting in complex hazard shapes. Standard parametric survival
models, as typically employed in TAs, are usually insufficiently
flexible to adequately describe these shapes.4,6
The development of potentially curative treatments has led to
an increased use of cure fraction models in TAs.7 During the recent
update of the methods used in National Institute for Health and
Care Excellence (NICE) TAs, cure fraction models were explicitly
identified as an option for consideration.8 Cure models were also
included in the recently published NICE decision support unit
technical support document on flexible methods for survival
analysis.9 Based on the results of simulation studies, the authors
concluded that when the truth contained a cure fraction, cure
models had lower bias than alternative methods. Nevertheless,
there are limitations with cure models. Reliable estimates of the
cure fraction require long follow-up; in practice estimates of the
cure fraction are very sensitive to model specification.4,10,11
Although there is a growing awareness of the importance of us-
ing a cure fraction model in TAs, there are limited examples of
their use; a recent review of NICE TAs did not find any reim-
bursement decisions that had been made based on a nonzero
cured fraction.7
A proper assessment of the performance of cure models re-
quires multiple data sets with full follow-up, so that models may
be fit to an interim data cut. This allows an evaluation of both
within-sample fit and extrapolation performance. In the absence
of suitable data, simulation studies may be used; to-date 2 sim-
ulations of cure models for extrapolation in TAs have been
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considered.7,9 These are limited because between them only 2
cure fraction models have been considered: a Weibull cure model
and a Royston-Parmar (RP) cure model with 2 internal knots.
There is a need for a comprehensive assessment of multiple cure
fraction models for extrapolating data with a cured fraction. The
primary aim of this study was to address this evidence gap by
comparing the overall goodness of fit, for both within-sample
estimates and extrapolations, of cure models when fit to data
containing a cure fraction. There were 2 secondary aims:
1. To identify the accuracy with which the true cure fraction was
estimated
2. To assess the impact of not incorporating external data, by
comparing extrapolations from cure models with extrapola-
tions from models that do not assume a cure fraction
Methods
To assess the extrapolation performance of models with a cure
fraction, a simulation study was used. The reporting of the
simulation study follows published guidance.12 Components of
the simulation study are reported based on their aims (provided in
the previous section), data-generating mechanism, methods,
estimands, and performance measures. The code used is provided
in Appendix 1 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.05.009.
Data-Generating Mechanism
The “true” survival and hazard functions were simulated from
a Weibull cure data-generating mechanism. Hazard and survival
functions are represented by a Weibull model for individuals who
will die of the disease. General population English life tables are
used for cured individuals.13 A Weibull model with shape (g) and
scale (L) values of 1.6 and 2.6, respectively, was used for uncured
individuals, and it was assumed that one-quarter of the sample
would be cured (r = 0.25). The shape and scale were arbitrarily
chosen, with the aim of providing disease-specific death within a
moderately short timeframe (mean disease-specific survival 2.33
years) and with few survivors beyond 8 years. The cure fraction
was arbitrarily chosen with the intention that it was not the ma-
jority of patients, but large enough to notably influence survival.
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(both of which are monotone increasing for this study). The in-
dividual components are provided in Appendix Figure 1 in Sup-
plemental Materials found at https://doi.org/10.1016/j.jval.2021.
05.009. A total of 9 scenarios were considered, with 200 data
sets simulated for each scenario. For each individual, survival




0.25 and 0.75, respectively. That is, uncertainty in survival (and
hence hazard) functions was simulated but it was assumed that
there was no uncertainty in the cure fraction. The 9 scenarios
corresponded to 3 different sample sizes (small = 100, medium =
300, large = 600) and 3 different lengths of follow-up (short = 2
years, medium = 4 years, long = 8 years). The longest follow-up
was chosen so that there were almost no uncured individuals
still alive. The shortest follow-up was chosen to be representative
of the lengths of follow-up often seen in cancer trials.14 Sample
sizes were chosen to represent typical sample sizes of cancer
treatments seen in TAs. Details on the 9 scenarios are provided in
Table 1. Figure 1 shows the simulated hazards for each scenario (in
gray) along with the true hazard (in black, which is the same for
each scenario). The short-term increase in the hazard function is
driven by deaths among the uncured population. The first turning
point occurs when the contribution of the cured population out-
weighs that of the uncured population, with the overall hazard
decreasing to that of the cured population. This is followed by a
long-term increase in the hazard function because of aging.
Estimand and Performance Measures
The estimand was the natural logarithm of the time-varying
hazard function lti . The use of the hazard function is preferable
to the survivor function because the latter is a cumulative
measure, so estimates will not be independent. The primary and
secondary performance measures were mean-squared error
(MSE) and bias. Both time-varying and summary performance
measures were considered. A time horizon of 40 years was used
(at which overall survival was 0.1%), with time-steps of 0.05
years. Appendix 1 in Supplemental Materials found at https://
doi.org/10.1016/j.jval.2021.05.009 provides further details and
justification.
Methods
For all the methods (models) discussed in this section, a brief
overview is provided. Further details on model specification (for
the noncured component) are provided in a previous
publication.15
A total of 4 types of cure fraction model were included. For
these, the correct background mortality was provided for the
cured group. Hence, the models estimated the cure proportion and
the hazard function for the uncured group.
1. Weibull cure model: this is the same as the data-generating
mechanism, so the model structure is correctly specified.
2. Lognormal cure model: the model structure is incorrectly
specified (misspecified) with regard to the true functional form
for the uncured group.
3. RP cure model. These introduce additional flexibility through
the use of piecewise cubic polynomials. Between 0 and 4 in-
ternal knots were considered for these spline-based models.
Models were fit on the hazard scale, so include as a special case
the Weibull cure model (zero knots). Hence, the model is
overspecified because it includes the correctly specified model
as a special case but allows for a range of more flexible models.
For each data set, the model with the lowest value of Akaike
information criterion (AIC) was used to generate
extrapolations.
4. Dynamic cured fraction models (DCFMs). These are models for
which parameters evolve dynamically over time, as modeled
by a time series (such as a random walk). A total of 2 models
were considered: a local trend model (a Weibull model with
dynamic parameters) and a damped trend model (as before,
but the trend in extrapolations is dampened over time until it
becomes 0). The local trend model is overspecified (it is the
same as the Weibull cure model if there is no parameter evo-
lution), while the damped trend model is incorrectly specified.
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Hence, in total 5 cure models were included. R version 3.5.3 (R
Core Team, Austria, Vienna) was used. All dynamic models were fit
using RStan (Stan Development Team, Columbia); the remaining
cure fraction models used the cuRe package (Jakobsen, Aalborg,
Denmark).16
A total of 4 classes of model without a cured fraction were
considered. Where multiple model specifications were possible,
model choice was based on minimizing AIC to provide an auto-
mated method that reflects current approaches to model choice.17
One exception was the Gompertz, which was excluded from the
main results because the majority of extrapolations lacked face
validity.
1. Current practice. These models were designed to reflect the
models currently used in TAs.6 A total of 6 models were eval-
uated: exponential, Weibull, lognormal, log-logistic, gamma,
and generalized gamma. One model was retained. Results
including the Gompertz are provided in Appendix Figure 2 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.05.009. Fitting used the flexsurv package (Jackson, Cam-
bridge, England).18
2. Fractional polynomials (FPs). These represent the outcome as a
sum of polynomial terms. First-order FP and second-order FP
models were considered, where the order denotes the number
of polynomial terms, fit using the stats package. A total of 8
Figure 1. Simulated hazards (gray lines) for the 9 scenarios, along with the truth (black line).
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Table 1. Details of the 9 scenarios simulated.
Scenario Follow-up (survival %) Sample size
Short follow-up, small sample size 2 years (63.9%) 100
Short follow-up, medium sample size Cured = 97.7% 300
Short follow-up, large sample size Uncured = 52.6% 600
Medium follow-up, small sample size 4 years (34.8%) 100
Medium follow-up, medium sample size Cured = 95.5% 300
Medium follow-up, large sample size Uncured = 14.5% 600
Long follow-up, small sample size 8 years (22.7%) 100
Long follow-up, medium sample size Cured = 90.1% 300
Long follow-up, large sample size Uncured = 0.3% 600
-- 3
first-order FP and 36 second-order FP models were considered;
1 model was retained for each.
3. Spline-based models. A total of 2 implementations were eval-
uated. One used the generalized additive models implemented
in the mgcv package (Wood, Edinburgh, Scotland),19 which
incorporates penalization (via shrinkage of parameter esti-
mates) during model fitting, removing the decision of how
many knots to use. The second was the RP model (RPM), with
up to 5 internal knots (no internal knots being the same as the
Weibull model), as estimated by the flexsurv package, with 1
RPM retained.18
4. Dynamic survival models (DSMs). A total of 2 DSMs were used:
a local trend DSM and a damped trend DSM.
This provided 7 models for which goodness of fit was
examined.
Results
For the 9 scenarios considered, varying the length of follow-up
had a larger impact on results than varying the sample size. Hence
detailed results are presented for the 3 follow-ups (2, 4, 8 years),
with a sample size of 300. Summary results are provided for the
remaining 6 scenarios.
Cure Models
A visual comparison of the model estimates and the true log-
hazards is provided in Figure 2. With the shortest follow-up, all
the considered models provided poor predictions. The Weibull
cure and RP cure models both resulted in very similar extrapola-
tions; exhibiting the largest variation of the 5 models considered
with both overestimates and underestimates of the true hazard.
This similarity was because for most simulations (78%) the RP cure
model chose zero internal knots, resulting in a Weibull cure
model. The mean number of internal knots ranged from 0.32 to
0.55 across the 9 scenarios. Extrapolations from the DCFMs
underestimated the true hazards while the lognormal cure model
provided extrapolations that nearly always overestimated the
truth. For the shortest follow-up, increasing the sample size led to
less variation in extrapolations from the lognormal cure model
(but not improvement in fit) and had a negligible impact on ex-
trapolations from the remaining 4 cure models. For all 5 cure
models visual goodness of fit improved as the length of follow-up
increased; with the longest follow-up, all the cure models pro-
vided very good fits except for the misspecified lognormal cure
model, which continued to systematically overestimate the truth.
Summary measures of MSE and bias averaged over the entire
time horizon are provided for all 9 scenarios in Table 2, along with
a rankogram in Appendix Figure 3 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2021.05.009. A rankogram
displays the average number of times each model achieved each
rank based on its goodness of fit (where 1 is the best and 5 the
worst). Time-varying performance measures are provided in
Appendix Figures 4, 5 and Appendix Table 1 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2021.05.009. The
within-sample 95% confidence intervals all included zero, with
point estimates very close to zero, indicating that within-sample
Figure 2. Estimates of the log-hazard compared with the truth: cure fraction models.
DCFM indicates dynamic cured fraction model; RPM, Royston-Parmar model.
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bias was small and within an acceptable range. Similar
within-sample results were obtained for MSE values which, when
compared with the range of MSE values for the extrapolated
period, were very minor. In the scenarios with the longest follow-
up, all the models apart from the lognormal had overall (within-
sample and extrapolated period) MSE and bias values that were
very close to zero. Furthermore, except for the lognormal,
extrapolation performance and overall goodness of fit of the
models generally increased as the length of follow-up or the
sample size increased. The lognormal cure model had similar
within-sample fit to the other models; the poor overall perfor-
mance of this model was due to it providing poor extrapolations,
which remained biased even with 8 years follow-up.
The results of the rankogram further illustrate the poor per-
formance of the lognormal model. The remaining 4 models typi-
cally had similar MSE values, while the 2 DCFMs usually had the
lowest bias values. Hence, for the nondynamic cure models, model
misspecification (using a lognormal cure model instead of a
Weibull cure model) led to reduced extrapolation performance,
while using an overspecified model (RP cure model) had a negli-
gible impact on bias. The overall goodness of fit of the DCFMs was
similar to that of the correctly specified Weibull cure model,
despite being overspecified (local trend) or misspecified (damped
trend). Across the 9 scenarios, the Weibull cure model and dam-
ped trend cure models had the lowest MSE in 4 scenarios each.
The remaining scenario had the least mature data (follow-up 2
years and sample size = 100). For this, the lognormal cure model
provided the best MSE as its extrapolations had very low vari-
ability. The second lowest MSE was from a DCFM in 6 scenarios
and the RP cure model in the remaining 3.
Estimates of the Cure Fraction
Estimates of the cure fraction for each model and each scenario
are provided in Figure 3. For the shortest follow-up, none of the
models provided accurate estimates of the cure fraction; on
average, the lognormal cure model underestimated the true value,
while the remaining models overestimated it. Increasing length of
follow-up led to more accurate and less variable estimates,
although, even at the longest follow-up (when virtually all the
uncured patients had died), the lognormal provided an underes-
timate of the cure fraction.
In general, the Weibull cure and RP cure models provided
slightly more accurate estimates of the true cure fraction than the
2 DCFMs. Nevertheless, this did not correspond to improved
goodness of fit. This was most notable for the scenarios with
shortest follow-up, for which both DCFMs had better overall MSE
despite substantially overestimating the cured fraction (range for
mean estimates: DCFMs 44.5%-45.3%, Weibull cure and RP cure
models 30.3%-34.7%).
Models Without a Cure Fraction
Visual extrapolations from the models that do not include a
cured fraction are provided in Figure 4. Without external evidence,
none of the models provided accurate extrapolations for any of the
scenarios considered. As such, estimates of bias and MSE are not
quantified because there is little merit in identifying the model
with the best goodness of fit when none of the models are useful.
The poor performance of these models is because, without
external evidence, they are unable to describe the unobserved
long-term increase in hazards beyond the follow-up period.
Distinct extrapolation patterns may be seen for the current
practice models. These patterns arise from the selection of
different parametric models; results for the individual models
(including the Gompertz) are shown in Appendix Figure 2 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.05.009. For the scenarios with short-to-medium follow-up,
despite all the models (excluding the exponential) having very
similar within-sample fit years (range in mean MSE values: 0.01-
0.04), extrapolations varied markedly; extrapolations from the
Gompertz, Weibull, and gamma all increased, and those from the
log-logistic and lognormal decreased, while the generalized
gamma provided extrapolations that could increase or decrease.
This highlights the danger in basing model choice on within-
sample goodness of fit, because models with near-identical
within-sample fit could provide qualitatively discrepant extrapo-
lations (with no models providing accurate extrapolations).
The impact of within-sample goodness of fit on model choice
was also explored for the choice of using a cure model versus a
current practice or RPM. Appendix Table 2 in Supplemental Ma-
terials found at https://doi.org/10.1016/j.jval.2021.05.009 provides
the average absolute improvement in AIC by scenario when using
a cure model in preference to its noncure alternative (the focus is
on AIC because in practice MSE and bias are unknown, and AIC
cannot be calculated for the dynamic models). On average, the use
of a cure model led to an improved within-sample fit for all 9
scenarios, with larger improvements in more data-rich scenarios
(longer follow-up or increased sample size). Nevertheless, in the
scenarios with the least data, there was very little difference be-
tween cure fraction models and their corresponding noncure
models, suggesting that it would be difficult to choose between
the models in these situations. Given that extrapolations varied
Table 2. Goodness of fit over the entire time horizon: cure fraction models.
Measure and model Sample size: 100. Follow-up: Sample size: 300. Follow-up: Sample size: 600. Follow-up:
2 years 3 years 4 years 2 years 3 years 4 years 2 years 3 years 4 years
Overall mean squared error
Weibull cure model 1.73 0.34 0.04 1.35 0.14 0.01 0.84 0.04 0.01
Lognormal cure model 0.85 0.87 0.23 0.87 1.04 0.17 0.92 1.06 0.17
Royston-Parmar cure model 1.77 0.34 0.06 1.36 0.31 0.02 0.91 0.22 0.01
Local trend cure model 0.90 0.13 0.07 0.70 0.08 0.02 0.66 0.06 0.01
Damped trend cure model 0.87 0.13 0.07 0.68 0.08 0.02 0.64 0.06 0.01
Overall bias
Weibull cure model 0.20 0.16 0.08 0.07 0.04 0.01 0.01 0.02 0.02
Lognormal cure model 0.33 0.45 0.48 0.49 0.59 0.60 0.18 0.20 0.21
Royston-Parmar cure model 0.08 0.12 0.08 0.05 0.10 0.07 0.01 0.02 0.02
Local trend cure model 20.42 20.37 20.37 20.10 20.08 20.07 20.04 20.03 20.02
Damped trend cure model 20.42 20.37 20.36 20.10 20.08 20.06 20.04 20.03 20.02
-- 5
markedly between cure and noncure models, this highlights the
difficulties with model specification in data-poor scenarios.
Practical Recommendations When Choosing a Survival
Model for Extrapolation
A key first step is to assess the plausibility of assuming that a
health technology will result in a fraction of patients being “cured”
and so only experiencing general population mortality. This is a
clinical question, emphasizing the importance of including
subject-matter specialists.
If there are clinical reasons to believe that there may be a cure
fraction, the results of this study suggest that models that make
weak structural assumptions should be preferred. These models
typically performed and the correctly specified model while
avoiding the sensitivity to model misspecification. This includes
the RP cure model and both DCFMs. The sensitivity of extrapola-
tions to the choice of survival model should be assessed in
sensitivity analyses. The choice of base-case model should be
guided by the plausibility of extrapolations, because good within-
sample fit does not guarantee accurate extrapolations. If multiple
models provide plausible extrapolations, the use of a damped
trend DCFM may be preferable. This is because this model
dampens any extrapolated trend, so partly mitigates the danger of
extrapolating an incorrect trend. Care should be taken to avoid
overinterpreting the estimated cure fraction. Owing to a lack of
identifiability, cure fraction models can provide accurate extrap-
olations even if the estimated cure fraction is wrong. If there is
uncertainty about the plausibility of a cure, this should be
assessed by using noncure models in sensitivity analyses.
By definition, the accuracy of extrapolations is not known in
practice and waiting for longer follow-up is typically not an op-
tion. The results of this article emphasize the importance of
follow-up on extrapolation accuracy; with short follow-up, there
is a danger that no model will provide useful predictions of the
future.
Discussion
Recent innovations in health technologies have led to some
patients experiencing long-term survival. Generating accurate
extrapolations in the presence of a cured fraction is important but
challenging. This article compared the within-sample and
extrapolation performance of models with and without a cure
fraction when fit to data with a cured fraction. The use of models
with a cured fraction led to generally acceptable extrapolations. In
contrast, noncure models failed to provide plausible extrapola-
tions even at 8 years of follow-up, when over three-quarters of the
sample had died. Nevertheless, at the shortest follow-up consid-
ered (2 years, with over a third of the sample dead), even the
correctly specified Weibull cure model provided poor
extrapolations.
Of the cure models considered, the Weibull and lognormal
models both make strong structural assumptions about the shape
of the disease-specific hazard: that it is either monotonic or has a
single turning point, respectively. The results shown here suggest
Figure 3. Estimates of the cure fraction.
RPM indicates Royston-Parmar model.
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that when these strong structural assumptions are incorrect,
resulting extrapolations can be poor. In contrast, the cure RPM and
DCFMs make very weak structural assumptions and provided
extrapolations that were similar to the correctly specified model
across the scenarios considered. In particular, the misspecified
damped trend cure fraction model had the lowest overall MSE in 4
of the 9 scenarios and the second lowest in a further 2. As antic-
ipated, the correctly specified Weibull cure model led to the most
accurate estimates of the cure fraction for the cure models
considered, on average. Nevertheless, this did not result in
improved goodness of fit, which is influenced by estimates of both
the cure fraction and the hazard function for the uncured fraction.
Furthermore, with short follow-up, estimates from the Weibull
cure model were also highly variable while within-sample fit was
no better than that from a noncure Weibull model. Together these
highlight the lack of identifiability for data with a cure fraction;
where the cure fraction is unknown, the overall observed hazard
function may be described equally well by different combinations
of disease-specific hazard functions and cure fractions.
There is limited assessment of the performance of cure fraction
models in the literature. An analysis of long-term ovarian cancer
registry data, using Weibull cure and lognormal cure models,
showed both that estimate of the cure fraction was sensitive to
model choice and that the Weibull cure model provided more a
plausible estimate despite having a worse within-sample fit. The
authors also cautioned that “The estimate of the cure fraction can
be unstable when there are a small number at risk toward the end
of follow-up.”11 Stedman et al20 also used registry data and
demonstrated that estimates of the cure fraction were sensitive to
both the length of follow-up and model choice and to cancer site
and stage. The results of this study confirm the findings of these
studies, by showing that estimates of the cure fraction are strongly
influenced by the length of follow-up and can vary by model.
Grant et al7 performed a case study to assess the performance of
Weibull cure models when applied to data representative of a
NICE appraisal, with an overall cure fraction of 40% and the ma-
jority of uncured people dead by 150 months. Models fit to 40
months of follow-up were found to fit the observed data well but
underestimate the overall cure fraction and provide visually poor
extrapolations. Their findings support the findings of this study in
demonstrating that extrapolation with short follow-up (relative to
lifetime follow-up) can provide poor extrapolations, even if
within-sample fit is good. A simulation study performed by
Rutherford et al9 demonstrated that, if the truth includes a cure
fraction, cure models will provide better extrapolations than
noncure models; similar results were observed in this study.
This is the first time that the within-sample and extrapolation
performance of DCFMs has been assessed. In total, 69 models were
considered (9 cure models, 60 noncure), with 11 models retained
for estimating extrapolation performance (4 cure models, 7 non-
cure). This allows for an assessment of the impact that model
misspecification has on both goodness of fit and model selection
in practice. This includes both misspecifying the model for
disease-specific mortality in a cure fraction model and the
Figure 4. Estimates of the log-hazard compared with the truth: models without a cure fraction.
DSM indicates dynamic survival model; FP1, first-order fractional polynomial; FP2, second-order fractional polynomial; GAM, generalized additive model;
RPM, Royston-Parmar model.
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misspecification of not using a cure fraction model for data with a
cure fraction. For the former, the use of a misspecified current
practice model did not affect within-sample fit but led to very
poor and consistently biased extrapolations. In contrast, the use of
a misspecified DCFM had little effect. For all model classes, the use
of a model without a cured fraction provided extremely poor
extrapolations.
A potential limitation of this study is that the results only
represent an upper bound on the performance of the cure models
in practice. This is because for this study it has been assumed that
the survival of the cured patients is known with certainty (the
same life tables are used in the data-generating mechanism and
the models). In practice, there will be some misspecification; in-
dividual patient characteristics and local geographical factors may
lead to survival that is different to national life tables. This would
affect absolute goodness of fit but is unlikely to affect the relative
performance of the models assessed. The hazard function of the
uncured population is also relatively simple, arising from a
monotonic Weibull model. In reality the hazard function may not
be monotonic (eg, because of patient heterogeneity in survival),
which again may hamper extrapolation performance. This is likely
to most affect the Weibull cure and lognormal cure models,
because this study has demonstrated that extensions to current
practice models are sensitive to model misspecification. This
simulation study also only assessed 1 set of parameters for 1 data-
generating mechanism. Future research could continue to assess
the goodness of fit of cure models with different data-generating
mechanisms or in situations with real data with long follow-up
where a proportion of the sample are known to be cured. This
could include situations where the “cured” fraction have a mor-
tality that is persistently elevated compared with the general
population. In addition, it would be beneficial to know whether
cure versions of RPMs are affected by misspecification (do not
include the true model as a special case). This article has illus-
trated the impact of length of follow-up on extrapolation perfor-
mance. Further research to identify the situations when there is
sufficient follow-up to provide reliable extrapolations would be
valuable, particularly for situations such as rare diseases when it
may be difficult to obtain large sample sizes or long follow-up.
Future studies could also expand the data-generating mecha-
nism to consider the impact of disease progression on both sur-
vival and censoring, as was modeled in the study of Grant et al.7
Conclusions
The presence of a cure fraction creates complex hazard pat-
terns that can pose a challenge for extrapolation. Extensions of
current practice models to incorporate a cure fraction work well
if they match the true data-generating mechanism but can
provide poor results otherwise. Dynamic models with a cure
fraction generally performed and the correctly specified model,
while avoiding the sensitivity to model misspecification. For all
the models evaluated, incorrectly omitting the cure fraction led
to very poor extrapolations. When the truth did include a cure
fraction, all the cure models provided poor extrapolations at the
shortest follow-up considered, and in the data-poor scenarios,
there was little difference in the within-sample fit of cure and
noncure models. Hence, incorporating external data, in the form
of general population hazards, can in some situations improve
extrapolation performance but it is not guaranteed to do so. It is
not a substitute for having both adequate follow-up and subject-
matter input into the plausibility of assuming a cure fraction.
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